Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease
| Autor: | Claude M. Wischik, Christopher Paul Larch, Charles R. Harrington, Scott Clunas, Janet Elizabeth Rickard, Colin Marshall, Steven Kemp, John Storey, James Peter Sinclair, Michael Simpson, Ishaq Ahtsham, Sarah L. Nicoll, Lynda Jane Storey, Kathleen A. Harrington, David Horsley |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Genetically modified mouse
Proteolysis Tau protein Mice Transgenic tau Proteins Protein aggregation Models Biological Protein Aggregation Pathological Biochemistry Cell Line Mice Protein Aggregates Neurobiology Alzheimer Disease Methylthioninium medicine Animals Humans Protein Interaction Domains and Motifs Molecular Biology biology medicine.diagnostic_test Tau Protein (Tau) Chemistry Brain Cell Biology medicine.disease Protein Aggregation Recombinant Proteins Methylene Blue Tauopathy Prion-like Processing biology.protein Biophysics LMTX Alzheimer's disease Intracellular Binding domain |
| Zdroj: | The Journal of Biological Chemistry |
| ISSN: | 0021-9258 |
| DOI: | 10.1074/jbc.m114.616029 |
| Popis: | Background: Tau aggregation inhibitors could treat Alzheimer disease. Results: Stable reduced forms of leucomethylthioninium (LMTX®) are active in blocking prion-like Tau aggregation in novel cellular models. Conclusion: The intracellular Ki (0.12 μm) is comparable with brain levels required for clinical benefit. Significance: LMTX® could treat Alzheimer disease. Alzheimer disease (AD) is a degenerative tauopathy characterized by aggregation of Tau protein through the repeat domain to form intraneuronal paired helical filaments (PHFs). We report two cell models in which we control the inherent toxicity of the core Tau fragment. These models demonstrate the properties of prion-like recruitment of full-length Tau into an aggregation pathway in which template-directed, endogenous truncation propagates aggregation through the core Tau binding domain. We use these in combination with dissolution of native PHFs to quantify the activity of Tau aggregation inhibitors (TAIs). We report the synthesis of novel stable crystalline leucomethylthioninium salts (LMTX®), which overcome the pharmacokinetic limitations of methylthioninium chloride. LMTX®, as either a dihydromesylate or a dihydrobromide salt, retains TAI activity in vitro and disrupts PHFs isolated from AD brain tissues at 0.16 μm. The Ki value for intracellular TAI activity, which we have been able to determine for the first time, is 0.12 μm. These values are close to the steady state trough brain concentration of methylthioninium ion (0.18 μm) that is required to arrest progression of AD on clinical and imaging end points and the minimum brain concentration (0.13 μm) required to reverse behavioral deficits and pathology in Tau transgenic mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|